Our Sponsors

VIPCoFCCGBroadridgeLink Market Services GmbHAHEADhermesDP DHLK+SSAPGeorgesonSuedzuckerWacker Chemie AGThomson ReutersEQS Group

Search

VIPsight

Corporate Governance – portrayed in the individual cultural and legal framework, from the standpoint of equity capital.

VIPsight is a dynamic photo archive, sorted by nations and dates, by and for those interested in CG from all over the world.

VIPsight offers, every month:
transparent and independent current information / comments / facts and figures on corporate governance locally and internationally,

  • written by local CG experts,
  • selected and structured by the Club of Florence,
  • financed by its initiator VIP and other sponsors with a background of “Equity and Advisory” interests.
     

VIPsight International


Article Index

 

 

Capital News

 

CTS Eventim: upswing

The CTS Eventim AG ticket sales organization recently migrated from the SDax index to the MDax-listing of the mid-sized groups where a vacancy had emerged after the departure of Tui. At present, the company, which has been traded since 2000, is setting its sights on the export market, in particular Latin America and Russia. Eventem announced that it has begun selling tickets for the2016 Olympics in Rio de Janeiro, and, furthermore, that it was recently commissioned for the ticketing for the Formula 1 event in Sochi in October. Last year Eventim posted a turnover of approximately 690 million Euros and a pre-tax revenue of some 121 million Euros.

 

DIC Asset: new bonds

La SDax-listed DIC Asset AG, has increased its September 2014 bond with a private placement of 50 million Euros. The volume of the real estate company’s bond is now up to 175 million Euros and, as originally planned, will fall due in September. The shares, which will be traded as Entry Standard on the Frankfurt bourse from the end of April onwards, and the company bonds listed as Prime Standard should proceed towards unification in June at the current price. The net revenue accruing from the placement is earmarked for repaying bank loans.

 

Mologen: resources for research

An increase in capital in April assured Prime Standard-listed Molgen AG revenue of some 28 million Euros. The Prime Standard-listed bio-tech concern issued 5,657,875 new shares to both German and international investors and at 5 Euros per share, existing shareholders were given indirect right of first refusal for 2.8 million new shares. The company placed a further 450,000 shares with existing shareholders by warrant and the remainder went to new investors by international private placement. Share capital increased by capital measure to over 22.6 million Euros. And the revenue of the transactions will be used to fund current clinical studies.